- Home
- CTNM vs OABI Comparison
CTNM vs OABI Comparison
Compare CTNM & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- OABI
- Stock Information
- Founded
- CTNM 2009
- OABI 2012
- Country
- CTNM United States
- OABI United States
- Employees
- CTNM N/A
- OABI N/A
- Industry
- CTNM
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- CTNM
- OABI Health Care
- Exchange
- CTNM Nasdaq
- OABI Nasdaq
- Market Cap
- CTNM 248.7M
- OABI 228.9M
- IPO Year
- CTNM 2024
- OABI N/A
- Fundamental
- Price
- CTNM $12.40
- OABI $1.66
- Analyst Decision
- CTNM Strong Buy
- OABI Strong Buy
- Analyst Count
- CTNM 4
- OABI 3
- Target Price
- CTNM $22.75
- OABI $6.67
- AVG Volume (30 Days)
- CTNM 246.0K
- OABI 437.1K
- Earning Date
- CTNM 11-05-2025
- OABI 11-11-2025
- Dividend Yield
- CTNM N/A
- OABI N/A
- EPS Growth
- CTNM N/A
- OABI N/A
- EPS
- CTNM N/A
- OABI N/A
- Revenue
- CTNM N/A
- OABI $23,027,000.00
- Revenue This Year
- CTNM N/A
- OABI N/A
- Revenue Next Year
- CTNM N/A
- OABI $44.99
- P/E Ratio
- CTNM N/A
- OABI N/A
- Revenue Growth
- CTNM N/A
- OABI 6.05
- 52 Week Low
- CTNM $3.35
- OABI $1.22
- 52 Week High
- CTNM $20.30
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- CTNM 69.65
- OABI 46.73
- Support Level
- CTNM $11.46
- OABI $1.54
- Resistance Level
- CTNM $13.09
- OABI $1.71
- Average True Range (ATR)
- CTNM 1.02
- OABI 0.09
- MACD
- CTNM -0.07
- OABI 0.01
- Stochastic Oscillator
- CTNM 74.89
- OABI 69.77
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.